FindTrial
Sign In

Role of Bumetanide in Treatment of Autism

Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04766177
Enrollment
80
Registered
2021-02-23
Start date
2021-01-01
Completion date
2030-12-01
Last updated
2021-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism

Brief summary

Role of bumetanide in Autism

Detailed description

Role of Bumetanide in Treatment of Autism spectrum disorder in children

Interventions

DRUGBumetanide

bumetanide 0.5 mg twice daily

DRUGPlacebo

placebo tablets twice daily

Sponsors

Sherief Abd-Elsalam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

1. All patients with ASD diagnosed by CARS rating Scale⩾30. 2. Age of patients range between (3-12) years.

Exclusion criteria

* Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with improved CARS score6 monthsthe patients with improved CARS score

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, ass. prof.
sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026